Development of a bispecific antibody targeting PD-L1 and TIGIT with optimal cytotoxicity

Programmed death-ligand 1 (PD-L1) and T cell immunoreceptor with Ig and ITIM domains (TIGIT) are two potential targets for cancer immunotherapy, early clinical studies showed the combination therapy of anti-PD-L1 and anti-TIGIT had synergistic efficacy both in the terms of overall response rate (ORR...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhong, Zhenwei, Zhang, Mengyao, Ning, Yanan, Mao, Guanchao, Li, Xiaopei, Deng, Qi, Chen, Xiaorui, Zuo, Dongliang, Zhao, Xiangyu, Xie, Ermin, Wang, Huajing, Guo, Lina, Li, Bohua, Xiao, Kai, He, Xiaowen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9606248/
https://www.ncbi.nlm.nih.gov/pubmed/36289396
http://dx.doi.org/10.1038/s41598-022-22975-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9606248/
https://www.ncbi.nlm.nih.gov/pubmed/36289396
http://dx.doi.org/10.1038/s41598-022-22975-7

Ejemplares similares